Researchers sought to determine whether a reduced dose of apixaban would be as effective as using full-dose apixaban in preventing recurrent VTE in patients with active cancer.

Penumbra (NYSE:PEN) announced today that it completed enrollment in the STORM-PE trial of its Lightning Flash system.

Penumbra has completed subject enrolment in the multi-centre, randomised controlled trial, STORM-PE, which assesses the computer-assisted vacuum thrombectomy (CAVT) using the company’s Lightning Flash ...

“If you have any risk factors for DVT, talk to your doctor about precautions you can take prior to long-distance travel,” ...

A new study has found a link between certain midlife vascular risk factors — specifically high blood pressure, diabetes, and ...

Penumbra, Inc. announced the completion of enrollment in the pivotal STORM-PE prospective, multicenter, randomized controlled tria ...

Two med-tech companies focused on pulmonary embolism overcame their own blockages to commercialization this week. Inquis ...

Teamwork: A Multidisciplinary Approach to Early Lung Cancer: Personalized Care A nurse practitioner with NYU's pulmonary intervention team chronicles the NSCLC patient experience from diagnosis to ...